ROSEN, A LEADING LAW FIRM, Encourages Orphazyme A/S Investors With Losses Over $100K to Secure Counsel Before Important September 7 Deadline in Securities Class Action – ORPH
03 août 2021 16h04 HE
|
The Rosen Law Firm PA
NEW YORK, Aug. 03, 2021 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Orphazyme A/S (NASDAQ: ORPH): (1) pursuant and/or...
Biotalys Nominates Catherine Moukheibir to its Board of Directors
10 juin 2021 02h00 HE
|
Biotalys
Ghent, BELGIUM, June 10, 2021 (GLOBE NEWSWIRE) -- Biotalys Nominates Catherine Moukheibir to its Board of Directors Highly respected finance and life sciences professional to chair company’s Audit...
Orphazyme to prepare for filing of arimoclomol in US for Niemann-Pick disease Type C (NPC)
21 juil. 2019 06h03 HE
|
ORPHAZYME A/S
Orphazyme A/SCompany announcement No. 18/2019Company Registration No. 32266355 ...
Orphazyme completes enrollment in phase 3 trial evaluating arimoclomol in Amyotrophic Lateral Sclerosis
18 juil. 2019 01h00 HE
|
ORPHAZYME A/S
Orphazyme A/SCompany announcement No. 17/2019 ...
Orphazyme to prepare for filing of arimoclomol in Europe for Niemann-Pick disease Type C (NPC)
07 juin 2019 00h56 HE
|
ORPHAZYME A/S
Orphazyme A/SCompany announcement No....
Orphazyme announces enrollment of first patient in Phase III clinical trial of arimoclomol for ALS
10 août 2018 12h19 HE
|
ORPHAZYME A/S
Orphazyme A/SCompany announcement No....
Orphazyme assumes sponsorship of Phase II/III sIBM trial
15 déc. 2017 09h20 HE
|
ORPHAZYME A/S
Investor newsNo. 01/2017 Orphazyme assumes sponsorship of Phase II/III sIBM trial On December 14, 2017, Orphazyme A/S, University of Kansas Medical Center, and UCL announced that Orphazyme...